[1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landmark Trial. Medscape. August 08, 2023. 跳转链接:[2]Regina...
图1 GLP1的主要心脏代谢作用 注:胰高血糖素样肽1(GLP-1)和GLP-1受体激动剂(GLP-1RA)作用于胰岛细胞、胃排空和中枢神经系统,改善葡萄糖稳态,同时降低食欲和体重,从而降低血压、改善肥胖和炎症。 CVOT中的GLP-1受体激动剂 目前已在临床中应用的GLP-1受体激动剂包括艾塞那肽、利拉鲁肽、度拉糖肽和司美格鲁肽...
[5] Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. [6] Howell E, Baumgartner HM, Zallar LJ, et al. Glucagon-LikePeptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT(2c)) Receptor Agonists in the Ventral Tegm...
【美迪西请回答】GLP-1 作用机制(Mechanisms of GLP-1)Medicilon 发布于:上海市 2023.10.16 16:29 分享到 热门视频 02:25 60岁大爷谈彩礼,独生子女应该如何养老? 00:46 智能脑起搏器远程程控 02:36 电影《机器人之梦》正片片段:机器人的绿野仙踪 10:55 途观L Pro 智能加持超进化 油车也能超聪明 ...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretio...
表1:临床研究中的GLP-1类似物(数据来源:汤森路透) 可以预期,随着研究的进一步开展,GLP-1在未来T2DM的治疗中将发挥更大作用,依从性和治疗效果更好的GLP-1产品将改善糖尿病患者的治疗现状。 参考文献: 1. Drucker DJ., et al. Mechanisms of Action and TherapeuticApplication of Glucagon-like Peptide-1. Cell...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide:...
[6] Cummings, D.E., Overduin, J., Shannon, M.H., Foster-Schubert, K.E., Conference,A.B.S.C. 2005. Hormonal mechanisms of weight loss and diabetes resolution after bariatricsurgery. Surg Obes Relat Dis 1:35...
DISCUSSION In the peripheral tissues, the majority of the effects of glucagon-like peptide 1 (GLP-1) are mediated by direct interaction with the specific tissue GLP-1 receptors Indirect mechanisms of action of GLP-1 occur in liver, adipose, and muscle tissues BACKGROUND GLP-1 is synthesised ...
[27] Ruttimann, E.B., Arnold, M., Hillebrand, J.J., Geary, N., Langhans, W. 2009. Intramealhepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneousmeal size in the rat via different mechanisms. Endocrinology 150:1174-1181. ...